Resources for Food and Drug Administration (FDA)

FDA approves first generic drug for restless leg syndrome

news.xinhuanet.com

The U.S. Food and Drug Administration approved on Friday the first generic versions of Requip (ropinirole hydrochloride) tablets for the treatment of moderate to severe Restless Legs Syndrome. The following companies have received approval to market ropinirole hydrochloride tablets: Roxane Laboratories Inc., Teva Pharmaceuticals USA, Par Pharmaceuticals Inc., and Mylan Pharmaceuticals Inc.

View the Resource

Share or bookmarklet this web page at: